Page 4,154«..1020..4,1534,1544,1554,156..4,1604,170..»

Category Archives: Transhuman News

NASA wins White House approval to extend life of space station

Posted: January 9, 2014 at 6:46 am

WASHINGTON The world's most expensive science project the $100-billion-plus International Space Station is poised to get four more years in orbit. According to documents obtained by the Orlando Sentinel, NASA plans to announce this week that it has White House approval to extend the station's operations through 2024.

The decision follows years of pressure by top NASA officials, who consider the station a crucial steppingstone to future exploration. But a four-year extension probably would cost NASA about $3 billion a year from 2021 to 2024. That's a major chunk of the agency's annual budget of about $17 billion, and a longer mission could force NASA to make tough financial decisions in the future.

The Obama administration's approval, however, doesn't guarantee that the station, which has been continuously occupied since 2000, will survive past its current end date of 2020. At some point, Congress must approve a NASA budget that includes an extension of the station's life. The plan also must get the support of whoever wins the White House in 2016, though the backing of President Obama now might make it harder for the next administration to say no.

Still, the move is expected to reassure NASA's international partners, which have wondered how long the U.S. plans to commit to the station. NASA's announcement will coincide with a visit to Washington this week by leaders of the world's space agencies.

"Arriving at this decision in a timely and coordinated fashion will, hopefully, prove beneficial to our international partners as they struggle with decisions on funding for their space programs," NASA Administrator Charlie Bolden wrote in an email to NASA and administration officials that praised the decision.

The announcement also has the potential of sending a signal to China, NASA's latest cosmic competitor.

In 2003, China became just the third country to launch an astronaut into space, and Beijing reportedly is making plans to assemble its own space station next decade.

By keeping the International Space Station operational, NASA can maintain its own symbol of technical advancement while limiting attempts by the Chinese to woo global partners for its outpost.

The symbolism is especially important for NASA because of the agency's recent struggles with its human exploration program.

After NASA retired the space shuttle in 2011, the U.S. lost the ability to ferry its astronauts to the station, which orbits about 220 miles above Earth. NASA is paying Russia about $1.7 billion through 2017 for the service.

Visit link:
NASA wins White House approval to extend life of space station

Posted in Space Station | Comments Off on NASA wins White House approval to extend life of space station

There is Only One Evolution

Posted: at 6:45 am

I have frequently pointed out that pharmaceutical companies acknowledge that animal models are not predictive for human response in terms of efficacy or toxicity. More evidence for this position comes from Robert G. Hunter in an article in Genetic Engineering & Biotechnology News.[1] Hunter: Having developed over the past 20 years into a global market recently estimated at $5 billion, in vitro and in silico products and services are now about the same size as the in vivo services (contract research organization) industry. If animal models worked well, there would be no need for industry to look at other options. Pharma does not love bunnies. Pharma loves money.

Matthew Herper addressed the problems in drug development in an article in Forbes.[2] Herper:

Theres one factor that, as much as anything else, determines how many medicines are invented, what diseases they treat, and, to an extent, what price patients must pay for them: the cost of inventing and developing a new drug, a cost driven by the uncomfortable fact than 95% of the experimental medicines that are studied in humans fail to be both effective and safe.

Animal models are relied on for the evaluation of both efficacy and safety.[3-9] Herper continues:

A new analysis conducted at Forbes puts grim numbers on these costs. A company hoping to get a single drug to market can expect to have spent $350 million before the medicine is available for sale. In part because so many drugs fail, large pharmaceutical companies that are working on dozens of drug projects at once spend $5 billion per new medicine. . . . This is crazy. For sure its not sustainable, says Susan Desmond-Hellmann, the chancellor at UCSF and former head of development at industry legend Genentech, where she led the testing of cancer drugs like Herceptin and Avastin. Increasingly, while no one knows quite what to do instead, any businessperson would look at this and say, You cant make a business off this. This is not a good investment. I say that knowing that this has been the engine of wonderful things.

This, in part, is why disease-specific drugs like Kalydeco, a drug for cystic fibrosis (CF) patients that have a specific genetic mutation, costs $294,000 per patient per year.

The reason animal models fail for drug development is that animals and humans are evolved systems that are differently complex. While morphological similarities exist, very small differences in the genetic make-up between species and between individuals of the same species means the predictive value for extrapolation is nil in the real world. (For more on this see Trans-Species Modeling Theory.) Moreover, if the concept of evolved, complex systems invalidates trans-species extrapolation in drug development, it is going to do the same when trans-species extrapolation involves any perturbation that affects higher levels of organization. So just based on the evidence from drug development we can safely say that disease research on mice, monkeys, or dogs is not going to result in knowledge that has predictive value for human patients. The literature confirms this.[10-21][[22]p19-33, 73-77] [23-25]

Compare the above to this recent statement from Michael E. Goldberg published in the Wisconsin State Journal: Nearly every medical advance from the last century is a product of responsible animal research, and animal models will continue to be important to medical progress. . . . Activists who claim animal research does not benefit humans are wrong. Animals are essential to medical progress in all fields of human disease. [26] This illustrates the dichotomy regarding animal models. Dr Goldberg is an animal modeler who does basic research, which he sells as applied research. Not surprisingly, Goldberg thinks animal modeling is great. He does not suffer loss of income or prestige when the knowledge from animal modeling fails to translate to human patients.

Pharma on the other hand, can actually measure the success or lack thereof of animal models in the form of drugs successfully brought to market and Pharma says it doesnt work. Remember, Pharma is a business and they do not care how they develop new drugs they just want to develop new drugs so they can make money. Also remember that there are not two different theories of evolution: one for drug development and another for basic science research or basic research masquerading as applied research. If animal modeling in drug development fails to be consistent with evolutionary biology, then it fails in general as well.

Image courtesy of Wkipedia Common http://en.wikipedia.org/wiki/File:Chromosomes_mutations-en.svg

Original post:
There is Only One Evolution

Posted in Genetic Engineering | Comments Off on There is Only One Evolution

Does the body’s immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

Posted: at 6:45 am

PUBLIC RELEASE DATE:

8-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 7, 2014Packaging replacement genes in viruses is an effective method to deliver them to target tissues, but the human body mounts an immune response against the virus. The systemic and local immune reactions induced by an adeno-associated virus (AAV)-based gene therapy to treat lipoprotein lipase deficiency, approved for use in Europe, does not affect the safety of gene therapy or expression of the replacement gene for at least one year after delivery, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Human Gene Therapy website.

Valeria Ferreira and coauthors, uniQure BV and Academic Medical Center, Amsterdam, the Netherlands, and University of Montreal and Chicoutimi Hospital, Quebec, Canada, evaluated measures of inflammation and adverse clinical events and the expression of a replacement lipoprotein lipase (LPL) gene that was injected intramuscularly into patients with LPL deficiency. The gene was packaged in an AAV vector, as described in the article "Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of Lipoprotein Lipase deficiency (LPLD) gene therapy."

"The clinical data published in this paper were critical to the approval of Glybera," says James Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. "Furthermore, they provide context for laboratory measurements of immune responses which apparently did not impact product performance."

###

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals are Human Gene Therapy Methods, published bimonthly and focused on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly and featuring data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Read this article:
Does the body's immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

Posted in Genetic Engineering | Comments Off on Does the body’s immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

New project on psychiatric, neurologic, and behavioral genetics

Posted: at 6:44 am

PUBLIC RELEASE DATE:

8-Jan-2014

Contact: Susan Gilbert gilberts@thehastingscenter.org 845-424-4040 x244 The Hastings Center

(Garrison, NY) The Center for Research on Ethical, Legal, and Social Implications of Psychiatric, Neurologic, and Behavioral Genetics at Columbia University Medical Center unveils its mission today with the launch of its website. Two Hastings Center research scholars are core faculty members of the new center, which was recently awarded a five-year grant from the National Human Genome Research Institute.

As understanding of the genetic contributions to psychiatric, neurologic, and behavioral (PNB) traits and disorders grows rapidly, this knowledge is quickly being translated into clinical practice. But the information presents particular ethical, legal, and social challenges because of what it could reveal about characteristics associated with individual identity and many of our most feared afflictions. Because of the potential for stigma linked to many PNB disorders and traits, this information may negatively affect how people view themselves and how others see them. Examination of the impact of PNB genetic information and consideration of the implications for normative judgments and public policy are therefore critically needed.

"Scientific findings regarding PNB traits must be discussed with special attention to the human and social context because such traits and disordersfrom Alzheimer's, schizophrenia, and depression to empathy, aggression, and intelligencecan touch our sense of who we are as persons," said Erik Parens, PhD, a senior research scholar at The Hastings Center. Parens and Josephine Johnston, LLB, MBHL, a Hastings Center research scholar and director of research, are core faculty members of the new center, based in the Department of Psychiatry. "The new center is uniquely situated to offer such attention."

The center is focusing on three areas: 1) the impact of PNB genetic information in clinical and research contexts on patients, family members, and clinicians, including effects on treatment choices, health and lifestyle decisions, identity, and self-image; 2) the impact of PNB genetic information in nonclinical contexts in which such information may affect perceptions of autonomy and responsibility for behavior, with a special focus on attributions of responsibility in the judicial process and in everyday life; and 3) data to suggest how PNB genetic information should be used in policy judgments related to clinical contexts (e.g., diagnostic and treatment decisions), research contexts (e.g., access to genetic data), and nonclinical contexts (e.g., legal rules and health policy).

Parens and Johnston will lead the new center's investigation into the meaning of PNB genetics information and how it should be used in policies and practices, as well as the translation of the center's work into formats that can inform policies and practices.

"Our center offers the opportunity to advance knowledge of the ethical, legal, and social implications of one of the most rapidly developing areas of genetics. Drawing on our empirical studies and input from key stakeholders, we will develop strategies to guide the use of PNB genetic data in clinical and research settings, as well as in courts, legislatures, and regulatory agencies," said Paul Appelbaum, MD, director of the center and of the Division of Law, Ethics and Psychiatry in the Department of Psychiatry at Columbia University College of Physicians and Surgeons. "By integrating empirical researchers with experts in ethics, economics, law, and public policy, we hope to point the way toward beneficial use of the latest scientific findings in this exciting new area of genetics."

###

Read more from the original source:
New project on psychiatric, neurologic, and behavioral genetics

Posted in Human Genetics | Comments Off on New project on psychiatric, neurologic, and behavioral genetics

County: Collecting DNA From Crime Victims Voluntary

Posted: at 6:44 am

Story by J. Israel Balderas / CBS 12 News West Palm Beach, Fla. -- Continuing coverage now on a CBS 12 news investigation.

We go back to the scene of the crime, where evidence was collected. But surprisingly, so was the victim's DNA.

The unanswered question for weeks: why?

It starts with two different women.

It's terrifying, I'm terrified, said Riviera Beach resident Gladys Cameron. I cant even sleep at night.

We were shocked, said Brenda Bonar, who lives in North Palm Beach. I mean, I will tell you, it took us a long time to figure out if we want to do this or not.

Both of them had similar experiences with two different police departments.

Gladys, with Riviera Beach police, who was perplexed when she needed help.

What? DNA? Really? Swap my mouth, my son's mouth, recalls Cameron. He was like, yeah!

And Brenda, who didnt know what to say to a North Palm Beach Police Department officer.

Follow this link:
County: Collecting DNA From Crime Victims Voluntary

Posted in DNA | Comments Off on County: Collecting DNA From Crime Victims Voluntary

Elephant shark genome decoded

Posted: at 6:44 am

Jan. 8 (UPI) -- The first shark genome decoded belongs to the slow-evolving elephant shark, providing researchers new insight into cartilaginous fish, and the differences between sharks and other bony vertebrates.

A team of international researchers, including researchers from the Max Planck Institute of Immunobiology and Epigenetics and San Francisco State University, have decoded the one billion DNA pairs found in the elephant shark genome and compared them to the 3 billion DNA pairs found in humans.

The findings, published in Nature, have given them a better understanding of why a shark's skeleton is largely composed of cartilage rather than bone, and why their immune system is simpler than that of humans.

The researchers found a family of genes missing that are critical for bone formation and found in most bony vertebrates. This family of genes enables other vertebrates to replace cartilage with bone and researchers believe they could use this data to better understand bone diseases like osteoporosis.

Analysis of genes linked to the immune system showed that sharks lacked T-helper lymphocytes, which until now were considered essential for fighting off viral and bacterial infections. But despite the absence of these lymphocytes the shark has a robust immune defense system.

It is obvious that sharks can efficiently deal with all kinds of infections without this particular cell type. This indicates that nature can come up with different solutions to the same problem, said Thomas Boehm, co-author and director at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg.

The study also provided evidence that elephant shark genome is the slowest evolving among all vertebrates. The study of a shark's genome is considered essential because they are the oldest living group of jawed-vertebrates that diverged from bony vertebrates about 450 million years ago.

[Max Planck Institute of Immunobiology and Epigenetics] [Nature]

Follow this link:
Elephant shark genome decoded

Posted in Genome | Comments Off on Elephant shark genome decoded

Slow-evolving elephant shark genome is first to be sequenced from cartilaginous fish

Posted: at 6:44 am

PUBLIC RELEASE DATE:

8-Jan-2014

Contact: Nan Broadbent nbroadbe@sfsu.edu 415-338-7108 San Francisco State University

SAN FRANCISCO -- A team of researchers including SF State Assistant Professor of Biology Scott Roy has sequenced the entire genome of the elephant shark, uncovering several features that may shed light on the evolution of bony vertebrates.

The study is the first whole-genome analysis of a cartilaginous fish. Cartilaginous fishes include sharks, rays and skates. Together with bony fish, birds, reptiles, amphibians and mammals, they make up the branch of jawed vertebrates on life's family tree.

The elephant shark genome is relatively small, consisting of slightly fewer than a billion DNA base pairs compared with 3 billion base pairs in humans. But this spare sequence has yielded some intriguing details, the researchers write. For instance, the elephant shark lacks the genes for secreted phosphoproteins, which may explain why their cartilage is not converted into bone as in the other jawed vertebrates.

They also lack the genes for several key immune system cells and protein receptors in the adaptive immune system, which provides carefully targeted defenses against specific disease threats. This finding, say the researchers, may suggest that the adaptive immune system in jawed vertebrates gradually became more elaborate over time.

One of the most notable features of the elephant shark's genome is its incredibly slow rate of evolution, said Roy. Even slower than in "living fossils" such as the coelacanth, the elephant shark's genome has not changed substantially in hundreds of millions of years.

This slow rate of evolution was uncovered in part by Roy's analysis of the genome's introns. Introns are the part of the genetic sequence that "interrupts" genes, and must be spliced out before the gene can be expressed. In vertebrates, these introns can be thousands of DNA letters long and must include their own splicing instructions.

There have been very few intron changes in the elephant shark genome, but this isn't entirely surprising, noted Roy, who has studied intron organization across a variety of organisms, including humans. "It's pretty well established in vertebrates that very little of this intron loss and creation occurs."

Read the original here:
Slow-evolving elephant shark genome is first to be sequenced from cartilaginous fish

Posted in Genome | Comments Off on Slow-evolving elephant shark genome is first to be sequenced from cartilaginous fish

Elephant shark genome decoded: New insights gained into bone formation and immunity

Posted: at 6:44 am

Jan. 8, 2014 An international team of researchers has sequenced the genome of the elephant shark, a curious-looking fish with a snout that resembles the end of an elephant's trunk.

The elephant shark and its cousins the sharks, rays, skates and chimaeras are the world's oldest-living jawed vertebrates. But their skeletons are made of cartilage rather than bone, making this group of vertebrates an oddity on the evolutionary tree.

Now, by comparing the genome of the elephant shark with human and other vertebrate genomes, researchers at Washington University School of Medicine in St. Louis and elsewhere have discovered why the skeleton of sharks is cartilaginous. An analysis of the creature's genome, published Jan. 9 in the journal Nature, offers new insights into the genetic basis of bone formation and the molecular origins of adaptive immunity, which provides organisms with a more sophisticated immune response to pathogens.

Collectively, the findings have important implications for understanding bone diseases such as osteoporosis and for developing more effective therapies to treat these conditions. Findings related to the elephant shark's immune system provide new opportunities for studying adaptive immunity in humans and for formulating new strategies to fine-tune the immune response.

"We now have the genetic blueprint of a species that is considered a critical outlier for understanding the evolution and diversity of bony vertebrates, including humans," said senior author Wesley Warren, PhD, research associate professor of genetics at The Genome Institute at Washington University School of Medicine. "Although cartilaginous vertebrates and bony vertebrates diverged about 450 million years ago, with the elephant shark genome in hand, we can begin to identify key genetic adaptations in the evolutionary tree."

Among the cartilaginous fishes, the elephant shark was selected for sequencing because of its compact genome, which is one-third the size of the human genome. The fish lives in the waters off the southern coast of Australia and New Zealand, at depths of 200 to 500 meters, and uses its snout to dig for crustaceans at the bottom of the ocean floor.

By analyzing the elephant shark genome and comparing it with other genomes, the scientists discovered a family of genes that is absent in the elephant shark but present in all bony vertebrates, including the chicken, cow, mouse and human. When the researchers deleted a member of this gene family in zebrafish, they observed a reduction in bone formation, highlighting the gene family's significance in making bone.

In a surprise finding, the team found that the elephant shark appears to lack special types of immune cells that are essential to mounting a defense against viral and bacterial infections and for preventing autoimmune diseases such as diabetes and rheumatoid arthritis.

However, despite possessing a relatively rudimentary immune system, sharks exhibit robust immune responses and live long lives. The new discovery opens up the possibility of developing new strategies to shape the immune response in humans.

The researchers also determined that the elephant shark genome is the slowest-evolving among all vertebrates, including the coelacanth, a prehistoric fish popularly known as a "living fossil."

More:
Elephant shark genome decoded: New insights gained into bone formation and immunity

Posted in Genome | Comments Off on Elephant shark genome decoded: New insights gained into bone formation and immunity

First shark genome decoded

Posted: at 6:44 am

Jan. 8, 2014 An international team of researchers, including scientists of the Max Planck Institute of Immunobiology and Epigenetics, has sequenced and analyzed the genome of the elephant shark. Comparison of the elephant shark genome with human and other vertebrate genomes has revealed why the skeleton of sharks is made up largely of cartilage and not bone like the human skeleton and that the immune system of the shark is much simpler than that of humans. The findings of Byrappa Venkatesh and his coworkers are published in the latest issue of the scientific journal, Nature.

An unexpected finding of the immune system analysis was that sharks appear to lack special types of so-called T-helper lymphocytes, that -- until now -- were considered to be essential for defence against viral/bacterial infections and preventing autoimmune reactions such as diabetes and rheumatoid arthritis in vertebrates.

Despite this seemingly primitive organization of the immune system, sharks exhibit robust immune defences and are long-lived. "The structure of the immune system of the elephant shark is very different from mammals," said Thomas Boehm, co-author and director at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany. "It is obvious that sharks can efficiently deal with all kinds of infections without this particular cell type. This indicates that nature can come up with different solutions to the same problem," stated Boehm.

What happens when T-helper cells are being destroyed can be observed in AIDS patients, who succumb to viral and bacterial infections. Up to now, it was assumed that cells are essential for an immune system. The new results are challenging this long-held notion and open up an unprecedented avenue towards the development of non-intuitive strategies to modulate the immune functions of humans.

The researchers also investigated why cartilaginous fishes, including the elephant shark, are unable to replace cartilage with bone like humans and other bony vertebrates. Genome analysis was able to highlight a family of genes that are absent in sharks but present in all bony vertebrates and are critical for bone formation. When the researchers inactivated these genes in bony fishes such as the zebrafish, calcification did not occur. This finding is a strong indication that the investigated gene family could be a starting point for a better understanding of bone diseases such as osteoporosis.

In addition, the study revealed that the elephant shark genome is the slowest evolving among all vertebrates. The elephant shark even beats the coelacanth, also called "the living fossil," that has recently been shown to evolve extremely slowly. Therefore, the elephant shark is probably the best proxy for the ancestor of all jawed-vertebrates that became extinct a long time ago.

Cartilaginous fishes (comprising sharks, rays, skates and chimaeras) are the oldest living group of jawed-vertebrates that diverged from bony vertebrates about 450 million years ago. The elephant shark (Callorhinchus milii) is a chimaera that inhabits temperate waters of the continental shelves off southern Australia and New Zealand, at depths of 200 to 500 meters. From approximately 1,000 species of cartilaginous fishes, elephant shark was chosen as a model because of its relatively compact genome which is one third the size of the human genome.

Here is the original post:
First shark genome decoded

Posted in Genome | Comments Off on First shark genome decoded

Cuomo sees $100 million genome center in Buffalo

Posted: at 6:44 am

ALBANY Gov. Andrew M. Cuomo unveiled an election-year grab bag of policy proposals Wednesday in his fourth State of the State, including funding for a genome research consortium between Buffalo and Manhattan, bonuses for top-performing public school teachers, modest tax breaks for property owners and tougher penalties for repeat drunk drivers and teens who text and drive.

Cuomo said he will dip again into his pledge made several years ago to spend $1 billion on Buffalo job creation efforts by authorizing a $100 million genome research program with $50 million going to the University at Buffalo and potentially other groups in the Buffalo area to connect scientists in Western New York with genome researchers at a new center in Manhattan.

Cuomo and researchers involved in the project said jobs and scientific breakthroughs to treat cancer and other diseases will result from the state investment. He said five companies already have committed to locate or expand on the Buffalo Niagara Medical Campus to be a part of a consortium with a not-for-profit genome center in Manhattan that opened last fall. Cuomo said the research work will create an entirely new industry for Western New York.

The 69-minute address also included a call for a major, $2 billion borrowing to fund new technological expansions and space for prekindergarten classrooms a bond program political analysts say is likely to bolster turnout in key geographic areas for an initiative that will appear on the same ballot as Cuomo in his first re-election bid this November.

A number of ideas, including expansion of abortion rights and taxpayer-financed campaigns, were rejected less than a year ago by Republicans who control the State Senate, and Cuomo made no mention, despite claims last fall to The Buffalo News that he would, about penalties or dramatic action for failing public schools.

Cuomo spent a third of his speech talking about what he called his accomplishments in his first three years, from a property tax cap to legalizing gay marriage to a sweeping gun-control measure.

In three years, my friends, you have reversed decades of decline, Cuomo told lawmakers in a state convention center near the Capitol.

Republican and Conservative Party leaders dismissed the Cuomo speech as election-year rhetoric with major new spending plans from a governor who should have embraced deeper tax cuts when he first took office.

In a hall with teeth-chattering temperatures, a favorite thermostat setting by this governor for his major, longer speeches, Cuomo offered the political spectrum of ideas in his address. For liberals, he said he will issue regulations to permit people with certain medical conditions to obtain marijuana to treat pain and other ailments at 20 hospitals around the state, seek to expand abortion rights, and raise the automatic, mandatory age from 16 to 18 at which teens arrested for crimes can be tried as an adult.

For right-of-center New Yorkers, he offered up a tax cut package for upstate manufacturers and beleaguered property taxpayers, a new state college focusing on counter-terrorism and homeland security and several criminal-justice measures, including crackdowns on repeat drunk drivers who he said should permanently lose their license if convicted of three DWI offenses.

Read more from the original source:
Cuomo sees $100 million genome center in Buffalo

Posted in Genome | Comments Off on Cuomo sees $100 million genome center in Buffalo

Page 4,154«..1020..4,1534,1544,1554,156..4,1604,170..»